{"id":836913,"date":"2025-04-14T08:29:32","date_gmt":"2025-04-14T12:29:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/"},"modified":"2025-04-14T08:29:32","modified_gmt":"2025-04-14T12:29:32","slug":"neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/","title":{"rendered":"NeOnc Technologies Holdings, Inc. Expects Full Enrollment\u00a0in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas\u00a0in September"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong><br \/>\n          <em>&#8212; Trial Read-Out Data Expected in Early 2026 <\/em><br \/>\n        <\/strong><br \/>\n        <em>&#8212;<\/em>\n      <\/p>\n<p>CALABASAS, Calif., April  14, 2025  (GLOBE NEWSWIRE) &#8212; <strong>NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI)<\/strong>, a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that it expects full enrollment in its Phase 2a clinical trial for its lead therapeutic candidate, NEO100-01 in September. Only six patients remain to complete the trial\u2019s 25-patient enrollment target.<\/p>\n<p>This landmark trial, for which read-out data is expected in early 2026, investigates NEO100, a proprietary, highly purified version of perillyl alcohol, delivered intranasally, a non-invasive method designed to bypass the blood-brain barrier through the olfactory and trigeminal nerves. NEO100-01 is the first intranasal therapy of its kind evaluated in malignant gliomas, particularly targeting IDH1 mutant Grade III and IV astrocytomas. Grade IV gliomas are among the most aggressive and deadly forms of brain cancer.<\/p>\n<p>\u201cWe believe our intranasal delivery mechanism can present a breakthrough in central nervous system oncology, potentially offering a practical and elegant route to circumvent the blood-brain barrier,\u201d said Dr. Thomas Chen, Chief Executive Officer and Chief Scientific Officer at NeOnc Technologies. \u201cEarly data from our Phase 1 study provides support that patients with IDH1 mutations experienced extended survival post-recurrence with minimal side effects. We are optimistic that this approach could transform treatment outcomes for this patient population.\u201d<\/p>\n<p>\u201cReaching near full enrollment in the NEO100-01 trial, with only six patients remaining, is a positive and exciting development,\u201d said Executive Chairman, Amir Heshmatpour. \u201cOur team believes we can meet the FDA\u2019s efficacy endpoints and deliver a positive outcome for patients battling these devastating tumors.\u201d<\/p>\n<p>NEO100 has been granted both Orphan Drug Designation and Fast Track Status by the U.S. Food and Drug Administration (FDA), reinforcing its potential as a significant advancement in the treatment of malignant gliomas.<\/p>\n<p>\n        <strong>ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.<\/strong><br \/>\n        <br \/>NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company\u2019s NEO\u2122 drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc\u2019s NEO100\u2122 and NEO212\u2122 therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.<\/p>\n<p>For more about NeOnc and its pioneering technology, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8pwUuNu4fLfYcr1UF1E1MHUS2ZXc-_51mcklFsopndJeTpmRPsm_Vyl29N84S6Z7zEnmqDhOQuJYQVOgIe81aQ==\" rel=\"nofollow\" target=\"_blank\"><u>neonc.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Important Cautions Regarding Forward Looking Statements <\/strong><br \/>\n        <br \/>All statements other than statements of historical facts included in this press release are &#8220;forward-looking statements&#8221; (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as &#8220;projected,&#8221; &#8220;expect,&#8221; &#8220;possibility&#8221; and &#8220;anticipate,&#8221; or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law.<\/p>\n<p>\u201cNEO100\u201d is a registered trademark of NeOnc Technologies Holdings, Inc.<\/p>\n<p>\n        <strong>Company Contact: <\/strong><br \/>\n        <br \/>Patrick Walters<br \/>Chief Operations Officer<br \/>NeOnc Technologies Holdings, Inc. <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Me0o6WkuWLAEDVV1DX2Z48HnS7x-es4HKV16ih5Bnuhsg-0PI7npK6xiSGN5tMqQmumRP4pK7Va1uRi7tU6R5Q==\" rel=\"nofollow\" target=\"_blank\">info@neonc.com<\/a><\/p>\n<p>\n        <strong>Investor Relations: <\/strong><br \/>\n        <br \/>Roger Pondel \/ Laurie Berman<br \/>PondelWilkinson Inc.<br \/>(310) 279-5980<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bagi5uaiAAa7taQOHd1sA7_XoicvmvE4J160IA1WaHH9GskljflIUzcy0e4aNBOk5TkZyoRFZZREswmD_QwskJGL6Mjar3_o93ZK9hE_o5I=\" rel=\"nofollow\" target=\"_blank\">rpondel@pondel.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Yee-vS5uNZXv8REjIvSOlh0qh8udou9IJLxYLCnYmQC9NDj5-oSExvCXZvuwRpjHia0KGmxqvE5XBFP9OMuXZYpSkiK_N2AxWuLcKgLHcx4=\" rel=\"nofollow\" target=\"_blank\">lberman@pondel.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTQzOCM2ODYzNzM2IzIyNTY4Mzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Nzg1ODE0MzQtODQyMC00YmNkLWIxNWMtMmRlYjNhNDk3OWUyLTEyNjgzODctMjAyNS0wNC0xNC1lbg==\/tiny\/NeOnc-Technologies-Holdings-In.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8212; Trial Read-Out Data Expected in Early 2026 &#8212; CALABASAS, Calif., April 14, 2025 (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that it expects full enrollment in its Phase 2a clinical trial for its lead therapeutic candidate, NEO100-01 in September. Only six patients remain to complete the trial\u2019s 25-patient enrollment target. This landmark trial, for which read-out data is expected in early 2026, investigates NEO100, a proprietary, highly purified version of perillyl alcohol, delivered intranasally, a non-invasive method designed to bypass the blood-brain barrier through the olfactory and trigeminal nerves. NEO100-01 is the first intranasal therapy of its kind evaluated &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeOnc Technologies Holdings, Inc. Expects Full Enrollment\u00a0in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas\u00a0in September&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-836913","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeOnc Technologies Holdings, Inc. Expects Full Enrollment\u00a0in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas\u00a0in September - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeOnc Technologies Holdings, Inc. Expects Full Enrollment\u00a0in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas\u00a0in September - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8212; Trial Read-Out Data Expected in Early 2026 &#8212; CALABASAS, Calif., April 14, 2025 (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that it expects full enrollment in its Phase 2a clinical trial for its lead therapeutic candidate, NEO100-01 in September. Only six patients remain to complete the trial\u2019s 25-patient enrollment target. This landmark trial, for which read-out data is expected in early 2026, investigates NEO100, a proprietary, highly purified version of perillyl alcohol, delivered intranasally, a non-invasive method designed to bypass the blood-brain barrier through the olfactory and trigeminal nerves. NEO100-01 is the first intranasal therapy of its kind evaluated &hellip; Continue reading &quot;NeOnc Technologies Holdings, Inc. Expects Full Enrollment\u00a0in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas\u00a0in September&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-14T12:29:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTQzOCM2ODYzNzM2IzIyNTY4Mzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeOnc Technologies Holdings, Inc. Expects Full Enrollment\u00a0in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas\u00a0in September\",\"datePublished\":\"2025-04-14T12:29:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\\\/\"},\"wordCount\":728,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMTQzOCM2ODYzNzM2IzIyNTY4Mzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\\\/\",\"name\":\"NeOnc Technologies Holdings, Inc. Expects Full Enrollment\u00a0in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas\u00a0in September - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMTQzOCM2ODYzNzM2IzIyNTY4Mzg=\",\"datePublished\":\"2025-04-14T12:29:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMTQzOCM2ODYzNzM2IzIyNTY4Mzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMTQzOCM2ODYzNzM2IzIyNTY4Mzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeOnc Technologies Holdings, Inc. Expects Full Enrollment\u00a0in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas\u00a0in September\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeOnc Technologies Holdings, Inc. Expects Full Enrollment\u00a0in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas\u00a0in September - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/","og_locale":"en_US","og_type":"article","og_title":"NeOnc Technologies Holdings, Inc. Expects Full Enrollment\u00a0in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas\u00a0in September - Market Newsdesk","og_description":"&#8212; Trial Read-Out Data Expected in Early 2026 &#8212; CALABASAS, Calif., April 14, 2025 (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that it expects full enrollment in its Phase 2a clinical trial for its lead therapeutic candidate, NEO100-01 in September. Only six patients remain to complete the trial\u2019s 25-patient enrollment target. This landmark trial, for which read-out data is expected in early 2026, investigates NEO100, a proprietary, highly purified version of perillyl alcohol, delivered intranasally, a non-invasive method designed to bypass the blood-brain barrier through the olfactory and trigeminal nerves. NEO100-01 is the first intranasal therapy of its kind evaluated &hellip; Continue reading \"NeOnc Technologies Holdings, Inc. Expects Full Enrollment\u00a0in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas\u00a0in September\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-14T12:29:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTQzOCM2ODYzNzM2IzIyNTY4Mzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeOnc Technologies Holdings, Inc. Expects Full Enrollment\u00a0in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas\u00a0in September","datePublished":"2025-04-14T12:29:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/"},"wordCount":728,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTQzOCM2ODYzNzM2IzIyNTY4Mzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/","name":"NeOnc Technologies Holdings, Inc. Expects Full Enrollment\u00a0in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas\u00a0in September - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTQzOCM2ODYzNzM2IzIyNTY4Mzg=","datePublished":"2025-04-14T12:29:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTQzOCM2ODYzNzM2IzIyNTY4Mzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTQzOCM2ODYzNzM2IzIyNTY4Mzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-inc-expects-full-enrollment-in-promising-phase-2a-trial-of-neo100-01-for-malignant-gliomas-in-september\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeOnc Technologies Holdings, Inc. Expects Full Enrollment\u00a0in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas\u00a0in September"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/836913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=836913"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/836913\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=836913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=836913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=836913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}